Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1975 1
1977 10
1978 1
1979 2
1980 2
1981 2
1982 1
1983 3
1984 5
1985 3
1986 2
1987 5
1988 10
1989 4
1990 5
1991 1
1992 4
1993 6
1994 10
1995 10
1996 14
1997 11
1998 8
1999 6
2000 12
2001 13
2002 8
2003 13
2004 16
2005 11
2006 10
2007 9
2008 6
2009 16
2010 10
2011 6
2012 6
2013 5
2014 5
2015 6
2016 7
2017 1
2018 2
2019 7
2020 3
2021 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

292 results
Results by year
Filters applied: . Clear all
Page 1
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Duhen R, Ballesteros-Merino C, Frye AK, Tran E, Rajamanickam V, Chang SC, Koguchi Y, Bifulco CB, Bernard B, Leidner RS, Curti BD, Fox BA, Urba WJ, Bell RB, Weinberg AD. Duhen R, et al. Among authors: weinberg ad. Nat Commun. 2021 Feb 16;12(1):1047. doi: 10.1038/s41467-021-21383-1. Nat Commun. 2021. PMID: 33594075 Free PMC article. Clinical Trial.
Hypothermia.
Weinberg AD. Weinberg AD. Ann Emerg Med. 1993 Feb;22(2 Pt 2):370-7. doi: 10.1016/s0196-0644(05)80467-6. Ann Emerg Med. 1993. PMID: 8434836 Review.
OX40 (CD134) and OX40L.
Gough MJ, Weinberg AD. Gough MJ, et al. Among authors: weinberg ad. Adv Exp Med Biol. 2009;647:94-107. doi: 10.1007/978-0-387-89520-8_6. Adv Exp Med Biol. 2009. PMID: 19760068 Review.
Signaling through OX40 enhances antitumor immunity.
Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, Urba WJ, Weinberg AD, Curti B, Fox BA. Jensen SM, et al. Among authors: weinberg ad. Semin Oncol. 2010 Oct;37(5):524-32. doi: 10.1053/j.seminoncol.2010.09.013. Semin Oncol. 2010. PMID: 21074068 Free PMC article. Review.
Science gone translational: the OX40 agonist story.
Weinberg AD, Morris NP, Kovacsovics-Bankowski M, Urba WJ, Curti BD. Weinberg AD, et al. Immunol Rev. 2011 Nov;244(1):218-31. doi: 10.1111/j.1600-065X.2011.01069.x. Immunol Rev. 2011. PMID: 22017441 Free PMC article. Review.
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.
Moran AE, Kovacsovics-Bankowski M, Weinberg AD. Moran AE, et al. Among authors: weinberg ad. Curr Opin Immunol. 2013 Apr;25(2):230-7. doi: 10.1016/j.coi.2013.01.004. Epub 2013 Feb 14. Curr Opin Immunol. 2013. PMID: 23414607 Free PMC article. Review.
Progress in addressing disparities through comprehensive cancer control.
Weinberg AD, Jackson PM, DeCourtney CA, Cravatt K, Ogo J, Sanchez MM, Tortolero-Luna G, Rollins RL. Weinberg AD, et al. Cancer Causes Control. 2010 Dec;21(12):2015-21. doi: 10.1007/s10552-010-9649-8. Epub 2010 Nov 5. Cancer Causes Control. 2010. PMID: 21057869 Review.
292 results